Karyopharm Therapeutics Inc. Quarterly Income Tax Expense (Benefit) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Karyopharm Therapeutics Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2017 to Q3 2024.
  • Karyopharm Therapeutics Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $28K, a 133% increase year-over-year.
  • Karyopharm Therapeutics Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $296K, a 11.3% increase year-over-year.
  • Karyopharm Therapeutics Inc. annual Income Tax Expense (Benefit) for 2023 was $323K, a 12.5% decline from 2022.
  • Karyopharm Therapeutics Inc. annual Income Tax Expense (Benefit) for 2022 was $369K, a 37.7% increase from 2021.
  • Karyopharm Therapeutics Inc. annual Income Tax Expense (Benefit) for 2021 was $268K, a 13.3% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $296K $28K +$16K +133% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $280K $67K -$60K -47.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $340K $71K +$17K +31.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $323K $130K +$57K +78.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $266K $12K -$33K -73.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $299K $127K +$6K +4.96% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $293K $54K -$76K -58.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $369K $73K +$194K Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 $175K $45K -$61K -57.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $236K $121K -$13K -9.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $249K $130K -$19K -12.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $268K -$121K -$183K -295% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 $451K $106K +$62K +141% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $389K $134K -$3K -2.19% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $392K $149K +$83K +126% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $309K $62K +$60K +3000% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-17
Q3 2020 $249K $44K +$24K +120% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $225K $137K +$129K +1613% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $96K $66K +$56K +560% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $40K $2K -$15K -88.2% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $55K $20K +$6K +42.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-02
Q2 2019 $49K $8K +$25K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $24K $10K -$2K -16.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 $26K $17K +$8K +88.9% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-24
Q3 2018 $18K $14K +$1K +7.69% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-04
Q2 2018 $17K -$17K -$35K -194% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $52K $12K -$11K -47.8% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $63K $9K Oct 1, 2017 Dec 31, 2017 10-K 2020-02-26
Q3 2017 $13K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $18K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $23K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.